报价延迟最少15分钟:2025/07/18 18:14 EDT
盘后时段
|
||||
|
6.54 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.55
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.12/-0.62
|
|
企业价值
745.66M
|
| 资产负债 |
|
每股账面净值
2.39
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
169.58M
|
|
每股收益
4.37
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/18 18:14 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generatefuture cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales. |
